Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
3.93 USD
13.98 B USD
40.19 B USD
3.16 B
About Novo Nordisk A/S Class B
Sector
Industry
CEO
Maziar Mike Doustdar
Website
Headquarters
Bagsværd
Founded
1923
ISIN
DK0062498333
FIGI
BBG000K139Z3
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
N
XS300255582
Novo Nordisk Finance (Netherlands) BV 3.625% 27-MAY-2037Yield to maturity
3.59%
Maturity date
May 27, 2037
N
XS282046075
Novo Nordisk Finance (Netherlands) BV 3.375% 21-MAY-2034Yield to maturity
3.31%
Maturity date
May 21, 2034
N
XS300255353
Novo Nordisk Finance (Netherlands) BV 3.125% 27-MAY-2033Yield to maturity
3.12%
Maturity date
May 27, 2033
N
XS282045567
Novo Nordisk Finance (Netherlands) BV 3.25% 21-JAN-2031Yield to maturity
2.92%
Maturity date
Jan 21, 2031
N
XS300255329
Novo Nordisk Finance (Netherlands) BV 2.875% 27-AUG-2030Yield to maturity
2.85%
Maturity date
Aug 27, 2030
XS244124704
Novo Nordisk Finance (Netherlands) BV 1.375% 31-MAR-2030Yield to maturity
2.76%
Maturity date
Mar 31, 2030
N
XS282045460
Novo Nordisk Finance (Netherlands) BV 3.125% 21-JAN-2029Yield to maturity
2.63%
Maturity date
Jan 21, 2029
N
XS300255299
Novo Nordisk Finance (Netherlands) BV 2.375% 27-MAY-2028Yield to maturity
2.59%
Maturity date
May 27, 2028
XS234803042
Novo Nordisk Finance (Netherlands) BV 0.125% 04-JUN-2028Yield to maturity
2.48%
Maturity date
Jun 4, 2028
N
XS282044994
Novo Nordisk Finance (Netherlands) BV 3.375% 21-MAY-2026Yield to maturity
2.40%
Maturity date
May 21, 2026
XS244933017
Novo Nordisk Finance (Netherlands) BV 1.125% 30-SEP-2027Yield to maturity
2.40%
Maturity date
Sep 30, 2027
See all NONOF bonds
Curated watchlists where NONOF is featured.
Frequently Asked Questions
The current price of NONOF is 58.52 USD — it has decreased by −0.77% in the past 24 hours. Watch Novo-Nordisk A/S stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Novo-Nordisk A/S stocks are traded under the ticker NONOF.
NONOF stock has risen by 6.34% compared to the previous week, the month change is a 2.18% rise, over the last year Novo-Nordisk A/S has showed a −51.24% decrease.
We've gathered analysts' opinions on Novo-Nordisk A/S future price: according to them, NONOF price has a max estimate of 98.69 USD and a min estimate of 47.37 USD. Watch NONOF chart and read a more detailed Novo-Nordisk A/S stock forecast: see what analysts think of Novo-Nordisk A/S and suggest that you do with its stocks.
NONOF reached its all-time high on Jun 26, 2024 with the price of 149.55 USD, and its all-time low was 15.54 USD and was reached on Nov 23, 2016. View more price dynamics on NONOF chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
NONOF stock is 5.68% volatile and has beta coefficient of 1.55. Track Novo-Nordisk A/S stock price on the chart and check out the list of the most volatile stocks — is Novo-Nordisk A/S there?
Today Novo-Nordisk A/S has the market capitalization of 262.58 B, it has increased by 7.57% over the last week.
Yes, you can track Novo-Nordisk A/S financials in yearly and quarterly reports right on TradingView.
Novo-Nordisk A/S is going to release the next earnings report on Nov 5, 2025. Keep track of upcoming events with our Earnings Calendar.
NONOF earnings for the last quarter are 0.94 USD per share, whereas the estimation was 0.93 USD resulting in a 0.46% surprise. The estimated earnings for the next quarter are 0.87 USD per share. See more details about Novo-Nordisk A/S earnings.
Novo-Nordisk A/S revenue for the last quarter amounts to 12.11 B USD, despite the estimated figure of 12.12 B USD. In the next quarter, revenue is expected to reach 12.13 B USD.
NONOF net income for the last quarter is 4.18 B USD, while the quarter before that showed 4.21 B USD of net income which accounts for −0.76% change. Track more Novo-Nordisk A/S financial stats to get the full picture.
Novo-Nordisk A/S dividend yield was 1.83% in 2024, and payout ratio reached 50.28%. The year before the numbers were 1.35% and 50.35% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Sep 24, 2025, the company has 76.3 K employees. See our rating of the largest employees — is Novo-Nordisk A/S on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Novo-Nordisk A/S EBITDA is 25.32 B USD, and current EBITDA margin is 50.95%. See more stats in Novo-Nordisk A/S financial statements.
Like other stocks, NONOF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Novo-Nordisk A/S stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Novo-Nordisk A/S technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Novo-Nordisk A/S stock shows the neutral signal. See more of Novo-Nordisk A/S technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.